Home > PJ (current issue) > Letters | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7276 p711
22 November 2003

This page
Reprint
Photocopy

   

PDF* 120K

Letters

  Dispensing
  EpiPens
  Pharmacy practice
  Oxygen cylinders
  Overseas registration
  Statutory Committee
  The branches
  The Council
  The Charter


Letters to the Editor

Overseas registration

Judgements based on inexperience?

From Ms M. L. Stone

In the article about registration of overseas pharmacists (PJ, 18 October, p563), Linda Stone is quoted as saying that PharmDs appear to be taught at bachelor level. This simply is not true. A PharmD course is four years in duration and entry is only possible after completing a minimum of two years at an American college, though most students enter with three years of college credit or a bachelor’s degree. This makes the PharmD a minimum of six years at higher education level. Even considering that the first year of American college is really equivalent to “A”-levels, that leaves five years, which is equivalent to the MPharm plus one year of preregistration training.

In addition, my experience of the National Academic Recognition Information Centre for the United Kingdom (UK NARIC) is poor. One of the UK Research Councils also used UK NARIC, which advised it in one case that a student with a Danish master’s degree in pharmacy was not eligible to undertake a PhD studentship since the student did not have a bachelor’s degree. I argued to UK NARIC that the bachelor’s degree was encompassed within the master’s degree but UK NARIC would not budge. However, the Research Council finally saw sense and overruled UK NARIC.

I would question the level of knowledge and expertise of UK NARIC staff vis-à-vis professional degrees such as those in pharmacy. The person I dealt with at UK NARIC was junior and too inexperienced to be making pronouncements on the eligibility of Danish pharmacy students to do PhDs.

I hope that the Royal Pharmaceutical Society will seriously examine its procedures about equating overseas qualifications, because it seems to me that it is making judgements based on ignorance and inexperience. In a time of chronic pharmacist shortages, the Society’s attitude seems to be born of protectionism and not in the best interests of the public.

Margaret L Stone
Registrar, School of Pharmacy, University of London

 

KAREN MARSHALL, services manager, UK NARIC, replies:

UK NARIC is responsible for comparing academic levels based on learning outcomes and skills. Unfortunately this letter is based on a common misconception that equivalence is based solely on duration of a course, whereas in actual fact a number of factors must be considered. With regard to a PharmD from the United States, it is important to emphasise that the statements made in the letter are misleading. In the US, many professions are trained via a professional second degree, that is to say that a prior higher education qualification is required before the professional training element — but the academic level of the degree remains at first degree level.

With regard to Danish qualifications, again there appears to be a misunderstanding as our information clearly does not state that holders of the master’s degree cannot study at PhD level in the United Kingdom.

LINDA STONE, chairman, Adjudicating Committee, Royal Pharmaceutical Society, adds:

While ensuring that its decisions are consistent, transparent and robust, the Adjudicating Committee’s prime concern is public and patient safety. Entrants to the Register via the adjudicating route are required to demonstrate comparable critical skills and abilities as graduates from UK universities who now achieve a master’s level MPharm. Decisions taken by the committee must be objective, based on all available evidence.

UK NARIC is just one of several factors considered by the Adjudicating Committee and its limitations are appreciated.

The issue of the US PharmD is interesting. Length of study does not necessarily correlate to level of attainment. Although the PharmD might be equivalent to a UK doctorate in terms of years of study (six), in some cases it appears to be taught only at bachelor level. The graduate of such a bachelor level programme will not achieve the same skills as a UK MPharm graduate.

Send your letter to The Editor

Previous Topic (Oxygen cylinders)
Next Topic (Statutory Committee)

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal